Barclays upgraded Emerson (EMR) to Equal Weight from Underweight with a price target of $127, up from $125, following the Q3 report. The firm believes the process markets will be “fairly steady” into 2026. Market expectations for Emerson’s process and industrial capex outlook now appear more realistic, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: